An Integrated Approach to High-Throughput PK Profiling
Mar 18 2013
Successful drug discovery relies on the selection of drug candidates with good in vivo pharmacokinetic (PK) properties as well as appropriate preclinical efficacy and safety profiles. In vivo PK profiling is often a bottleneck in the discovery process. Charles River provides an integrated approach where all phases of discovery PK are performed such that the client interacts with a single point of contact on scientific matters, providing all of the information needed from formulation to data delivery.
Charles River Discovery Research Services offers short lead times for PK study initiation and a complete in-house formulations group with a wide range of standard vehicle components. Rodent and large animal models are available for single dosing, cassette dosing and repeat dosing by various routes (e.g., PO, IV, IP, IM, SC and intraduodenal).
In addition to our in-life PK offerings, we also offer non-GLP discovery bioanalytical services either in support of studies conducted in-house or as a stand-alone service with the flexibility and speed to meet the timelines and diverse needs for discovering the best drug candidate. Our research-grade assay approach via LC-MS/MS can quickly analyze samples for compound ranking and lead optimization. Once a lead candidate has been selected in the discovery analytical process, these methods can be transferred to method development for GLP bioanalytical testing including feasibility, validation and preclinical and clinical sample analysis.
In addition to drug concentration assessment, repeatable plasma and tissue biomarker analysis is equally important to the drug discovery process. With years of experience in assay design and sample processing, Charles River Discovery Biomarker Services provides biomarker analysis via clinical pathology and molecular and immunoassay testing platforms for in vitro, in vivo and ex vivo samples. We provide qualified and validated biomarker assays, and can also develop customized assays to accommodate multiple therapeutic areas and sample matrices.
To learn more about our high-throughput PK screening capabilities, click here or contact us at askcharlesriver@crl.com.
Related Information